FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761065707> ?p ?o ?g. }

• W2761065707 abstract "The aim of the present study was to assess the correlation between therapeutic response and carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) levels in advanced breast cancer patients with non-assessable lesions or stable disease (SD) according to the Response Evaluation Criteria in Solid Tumors. A total of 232 female patients with recurrent tumors following radical mastectomy were recruited, including 76 patients with non-assessable lesions and 60 patients with SD. The correlation between CEA and CA15-3 changes, progression-free survival (PFS) and therapeutic response were analyzed in the non-assessable and SD patient groups. For all subjects, the association between the patients' serum tumor markers levels and the clinical presentation of the tumor, as well as the correlation between initial tumor marker levels and PFS, were analyzed. An increase in CEA (an increment of >2 ng/ml) or CA15-3 levels (an increase of >15 U/ml) following the second cycle of treatment correlated with shorter PFS in both non-assessable and SD patients, and with poor clinical outcome in SD patients. High CA15-3 levels correlated with hormone receptor-positive tumors, multiple metastases and liver metastases. Bone metastases correlated with high levels of both CEA and CA15-3. Relatively low CEA and CA15-3 concentrations were associated with triple-negative and locally invasive tumors. High CEA and CA15-3 levels at the beginning of relapse correlated with shorter PFS. The present study illustrates that CEA and CA15-3 levels correlate with several factors in recurrent breast cancer patients. Elevated levels of CEA and CA15-3 at the beginning of relapse may predict shorter PFS. Furthermore, elevation of CEA and CA15-3 levels following the second therapeutic cycle predict poor therapeutic response in patients with non-assessable lesions and SD. Our findings suggest that alterations in CEA and CA15-3 levels can predict therapeutic response in advanced breast cancer patients." @default.
• W2761065707 created "2017-10-20" @default.
• W2761065707 creator A5014881515 @default.
• W2761065707 creator A5057561095 @default.
• W2761065707 creator A5064487127 @default.
• W2761065707 creator A5068716822 @default.
• W2761065707 creator A5069456938 @default.
• W2761065707 creator A5077791798 @default.
• W2761065707 date "2017-10-10" @default.
• W2761065707 modified "2023-09-23" @default.
• W2761065707 title "Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients" @default.
• W2761065707 cites W1906102489 @default.
• W2761065707 cites W1942836580 @default.
• W2761065707 cites W1968716940 @default.
• W2761065707 cites W1969508967 @default.
• W2761065707 cites W1969699501 @default.
• W2761065707 cites W1970850038 @default.
• W2761065707 cites W1974568982 @default.
• W2761065707 cites W1985683228 @default.
• W2761065707 cites W2003624069 @default.
• W2761065707 cites W2014535644 @default.
• W2761065707 cites W2016956014 @default.
• W2761065707 cites W2020256830 @default.
• W2761065707 cites W2025088897 @default.
• W2761065707 cites W2031257280 @default.
• W2761065707 cites W2033712867 @default.
• W2761065707 cites W2053533813 @default.
• W2761065707 cites W2055471823 @default.
• W2761065707 cites W2065236043 @default.
• W2761065707 cites W2066857931 @default.
• W2761065707 cites W2087678940 @default.
• W2761065707 cites W2090891576 @default.
• W2761065707 cites W2091196063 @default.
• W2761065707 cites W2091221538 @default.
• W2761065707 cites W2096065464 @default.
• W2761065707 cites W2098457595 @default.
• W2761065707 cites W2100230735 @default.
• W2761065707 cites W2105103603 @default.
• W2761065707 cites W2105161016 @default.
• W2761065707 cites W2110066719 @default.
• W2761065707 cites W2110238167 @default.
• W2761065707 cites W2117305280 @default.
• W2761065707 cites W2118075066 @default.
• W2761065707 cites W2119392662 @default.
• W2761065707 cites W2126659847 @default.
• W2761065707 cites W2131994307 @default.
• W2761065707 cites W2141046618 @default.
• W2761065707 cites W2153766359 @default.
• W2761065707 cites W2165948908 @default.
• W2761065707 cites W2170481258 @default.
• W2761065707 cites W2346549337 @default.
• W2761065707 cites W2355845524 @default.
• W2761065707 cites W2976006 @default.
• W2761065707 cites W4231259650 @default.
• W2761065707 doi "https://doi.org/10.3892/ol.2017.7164" @default.
• W2761065707 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5755157" @default.
• W2761065707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29344201" @default.
• W2761065707 hasPublicationYear "2017" @default.
• W2761065707 type Work @default.
• W2761065707 sameAs 2761065707 @default.
• W2761065707 citedByCount "14" @default.
• W2761065707 countsByYear W27610657072018 @default.
• W2761065707 countsByYear W27610657072020 @default.
• W2761065707 countsByYear W27610657072021 @default.
• W2761065707 countsByYear W27610657072022 @default.
• W2761065707 countsByYear W27610657072023 @default.
• W2761065707 crossrefType "journal-article" @default.
• W2761065707 hasAuthorship W2761065707A5014881515 @default.
• W2761065707 hasAuthorship W2761065707A5057561095 @default.
• W2761065707 hasAuthorship W2761065707A5064487127 @default.
• W2761065707 hasAuthorship W2761065707A5068716822 @default.
• W2761065707 hasAuthorship W2761065707A5069456938 @default.
• W2761065707 hasAuthorship W2761065707A5077791798 @default.
• W2761065707 hasBestOaLocation W27610657071 @default.
• W2761065707 hasConcept C118646709 @default.
• W2761065707 hasConcept C121608353 @default.
• W2761065707 hasConcept C126322002 @default.
• W2761065707 hasConcept C143998085 @default.
• W2761065707 hasConcept C2776869981 @default.
• W2761065707 hasConcept C2777387746 @default.
• W2761065707 hasConcept C2777701055 @default.
• W2761065707 hasConcept C2781018059 @default.
• W2761065707 hasConcept C29537977 @default.
• W2761065707 hasConcept C3019217517 @default.
• W2761065707 hasConcept C530470458 @default.
• W2761065707 hasConcept C71924100 @default.
• W2761065707 hasConcept C90924648 @default.
• W2761065707 hasConceptScore W2761065707C118646709 @default.
• W2761065707 hasConceptScore W2761065707C121608353 @default.
• W2761065707 hasConceptScore W2761065707C126322002 @default.
• W2761065707 hasConceptScore W2761065707C143998085 @default.
• W2761065707 hasConceptScore W2761065707C2776869981 @default.
• W2761065707 hasConceptScore W2761065707C2777387746 @default.
• W2761065707 hasConceptScore W2761065707C2777701055 @default.
• W2761065707 hasConceptScore W2761065707C2781018059 @default.
• W2761065707 hasConceptScore W2761065707C29537977 @default.
• W2761065707 hasConceptScore W2761065707C3019217517 @default.
• W2761065707 hasConceptScore W2761065707C530470458 @default.
• W2761065707 hasConceptScore W2761065707C71924100 @default.
• W2761065707 hasConceptScore W2761065707C90924648 @default.

• next